KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.

被引：6
|
作者：
Doi, Toshihiko
Bennouna, Jaafar
Shen, Lin
Enzinger, Peter C.
Wang, Ruixue
Csiki, Ildiko
Koshiji, Minori
Shah, Manish A.
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Inst Cancerol Ouest, Nantes, France
[3] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] MSD China, Beijing, Peoples R China
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Merck & Co Inc, Rahway, NJ 07065 USA
[8] Weill Cornell Med Coll, New York, NY USA
[9] New York Presbyterian Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4140
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4140
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
    Metges, J.
    Francois, E.
    Shah, M.
    Adenis, A.
    Enzinger, P.
    Kojima, T.
    Muro, K.
    Bennouna, J.
    Hsu, C.
    Moriwaki, T.
    Kim, S.
    Lee, S.
    Kato, K.
    Shen, L.
    Qin, S.
    Ferreira, P.
    Wang, R.
    Bhagia, P.
    Kang, S.
    Doi, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
    Shah, Manish A.
    Adenis, Antoine
    Enzinger, Peter C.
    Kojima, Takashi
    Muro, Kei
    Bennouna, Jaafar
    Francois, Eric
    Hsu, Chih-Hung
    Moriwaki, Toshikazu
    Kim, Sung-Bae
    Lee, Se-Hoon
    Kato, Ken
    Shen, Lin
    Qin, Shukui
    Ferreira, Paula
    Wang, Ruixue
    Bhagia, Pooja
    Kang, S. Peter
    Metges, Jean-Philippe
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Pembrolizumab versus investigator's choice single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma that progressed after first-line therapy: Phase 3 KEYNOTE-181 study
    Toshihiko, Doi
    Jaafar, Bennouna
    Lin, Shen
    Peter, Enzinger
    Wang Ruixue
    Rita, Dalal
    Minori, Koshiji
    Manish, Shah
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
    Muro, Kei
    Kojima, Takashi
    Moriwaki, Toshikazu
    Kato, Ken
    Nagashima, Fumio
    Kawakami, Hisato
    Ishihara, Ryu
    Ogata, Takashi
    Satoh, Taroh
    Iwakami, Keiichi
    Han, Shirong
    Yatsuzuka, Naoyoshi
    Takami, Tomoko
    Bhagia, Pooja
    Doi, Toshihiko
    ESOPHAGUS, 2022, 19 (01) : 137 - 145
  • [5] Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
    Kei Muro
    Takashi Kojima
    Toshikazu Moriwaki
    Ken Kato
    Fumio Nagashima
    Hisato Kawakami
    Ryu Ishihara
    Takashi Ogata
    Taroh Satoh
    Keiichi Iwakami
    Shirong Han
    Naoyoshi Yatsuzuka
    Tomoko Takami
    Pooja Bhagia
    Toshihiko Doi
    Esophagus, 2022, 19 : 137 - 145
  • [6] Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181
    Chen, J.
    Luo, S.
    Qin, S.
    Cheng, Y.
    Li, Z.
    Fan, Y.
    Yuan, X.
    Li, W.
    Sun, Y.
    Yin, X.
    Lin, X.
    Bai, Y.
    Liu, T.
    Zhang, J.
    Cui, Y.
    Bhagia, P.
    Kang, S. P.
    Lu, W.
    Zhou, Y.
    Shen, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy
    Kim, S-B.
    Doi, T.
    Kato, K.
    Chen, J.
    Shah, M.
    Adenis, A.
    Luo, S.
    Qin, S.
    Kojima, T.
    Metges, J-P.
    Francois, E.
    Muro, K.
    Cheng, Y.
    Li, Z.
    Yuan, X.
    Wang, R.
    Cui, Y.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
    Kojima, Takashi
    Shah, Manish A.
    Muro, Kei
    Francois, Eric
    Adenis, Antoine
    Hsu, Chih-Hung
    Doi, Toshihiko
    Moriwaki, Toshikazu
    Kim, Sung-Bae
    Lee, Se-Hoon
    Bennouna, Jaafar
    Kato, Ken
    Shen, Lin
    Enzinger, Peter
    Qin, Shu-Kui
    Ferreira, Paula
    Chen, Jia
    Girotto, Gustavo
    de la Fouchardiere, Christelle
    Senellart, Helene
    Al-Rajabi, Raed
    Lordick, Florian
    Wang, Ruixue
    Suryawanshi, Shailaja
    Bhagia, Pooja
    Kang, S. Peter
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (35)
  • [9] Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181
    Adenis, Antoine
    Kulkarni, Amit S.
    Girotto, Gustavo C.
    de la Fouchardiere, Christelle
    Senellart, Helene
    van Laarhoven, Hanneke W. M.
    Mansoor, Wasat
    Al-Rajabi, Raed
    Norquist, Josephine
    Amonkar, Mayur
    Suryawanshi, Shailaja
    Bhagia, Pooja
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04) : 382 - +
  • [10] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
    Kojima, Takashi
    Muro, Kei
    Francois, Eric
    Hsu, Chih-Hung
    Moriwaki, Toshikazu
    Kim, Sung-Bae
    Lee, Se-Hoon
    Bennouna, Jaafar
    Kato, Ken
    Lin, Shen
    Qin, Shi-Qui
    Ferreira, Paula
    Doi, Toshihiko
    Adenis, Antoine
    Enzinger, Peter C.
    Shah, Manish A.
    Wang, Ruixue
    Bhagia, Pooja
    Kang, S. Peter
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345